Bristol Myers SquibbBMYEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
Revenue
$12.5B
Gross Profit
$8.4B
Operating Profit
$1.5B
Net Profit
$1.1B
Gross Margin
67.2%
Operating Margin
11.8%
Net Margin
8.7%
YoY Growth
1.3%
EPS
$0.54
Bristol Myers Squibb Q4 FY2025 Financial Summary
Bristol Myers Squibb reported revenue of $12.5B (up 1.3% YoY) for Q4 FY2025, with a net profit of $1.1B (up 1409.7% YoY) (8.7% margin). Cost of goods sold was $4.1B, operating expenses totaled $6.9B.
Key Financial Metrics
| Total Revenue | $12.5B |
|---|---|
| Net Profit | $1.1B |
| Gross Margin | 67.2% |
| Operating Margin | 11.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Bristol Myers Squibb Q4 FY2025 revenue of $12.5B breaks down across 5 segments, led by Net Product Sales at $12.1B (96.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Net Product Sales | $12.1B | 96.9% |
| Zeposia | $159.0M | 1.3% |
| Opdivo Ovantig | $132.0M | 1.1% |
| Abecma | $100.0M | 0.8% |
| Sotyktu | $86.0M | 0.7% |
Bristol Myers Squibb Revenue by Segment — Quarterly Trend
Bristol Myers Squibb revenue by segment across the last 4 reported quarters, showing how each business line (such as Net Product Sales and Zeposia) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Net Product Sales | — | $12.1B | $11.8B | $11.9B |
| Zeposia | — | $159.0M | $161.0M | $150.0M |
| Opdivo Ovantig | — | $132.0M | $67.0M | $30.0M |
| Abecma | — | $100.0M | $137.0M | $87.0M |
| Sotyktu | — | $86.0M | — | $70.0M |
Bristol Myers Squibb Annual Revenue by Year
Bristol Myers Squibb annual revenue history includes year-by-year totals (for example, 2025 revenue was $48.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $48.2B |
| 2024 | $48.3B |
| 2023 | $45.0B |
| 2022 | $46.2B |
Bristol Myers Squibb Quarterly Revenue & Net Profit History
Bristol Myers Squibb results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $11.5B | +11.0% | $2.7B | 23.3% |
| Q4 FY2025 | $12.5B | +1.3% | $1.1B | 8.7% |
| Q3 FY2025 | $12.2B | +2.8% | $2.2B | 18.0% |
| Q2 FY2025 | $12.3B | +0.6% | $1.3B | 10.7% |
| Q1 FY2025 | $11.2B | -5.6% | $2.5B | 21.9% |
| Q4 FY2024 | $12.3B | +7.5% | $72.0M | 0.6% |
| Q3 FY2024 | $11.9B | +8.4% | $1.2B | 10.2% |
| Q2 FY2024 | $12.2B | +8.7% | $1.7B | 13.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B |
| YoY Growth | 8.7% | 8.4% | 7.5% | -5.6% | 0.6% | 2.8% | 1.3% | 11.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B | N/A |
| Liabilities | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B | N/A |
| Equity | $17.02B | $17.14B | $16.34B | $17.39B | $17.43B | $18.55B | $18.47B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $2.33B | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B |